Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals

Journal of the National Cancer Institute

Volumn 84, Issue 22, 1992, Pages 1716-1724

  Zugmaier, Gerhard ^a   Lippman, Marc E ^a   Wellstein, Anton ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; PENTOSAN POLYSULFATE; TRANSFORMING GROWTH FACTOR ALPHA;

AFFINITY CHROMATOGRAPHY; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL CULTURE; TUMOR GROWTH;

ANIMAL; BIOLOGICAL RESPONSE MODIFIERS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTORS; HEPARIN; HUMAN; IN VITRO; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PENTOSAN SULFURIC POLYESTER; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0026472599     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.22.1716     Document Type: Article

References (33)

1. Cross M, Dexter TM: Growth factors in development, transformation, and tumorigenesis. Cell 64:271–280, 1991
2. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327–336, 1991
3. Dickson RB, Lippman ME: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8:29–43, 1987
4. Folkman I, Klagsburn M: Angiogenic factors. Science 235:442–447, 1987
5. Folkman J: Tumor angiogenesis. Adv Cancer Res 43:175–203, 1985
6. Folkman J: Antiangiogenesis. In Biologic Therapy of Cancer (De Vita VT Jr, Hellman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1991, pp 743–753
7. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324:1–8, 1991
8. Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136–139, 1982
9. Denekamp J: The current status of targeting tumour vasculature as a means of cancer therapy: An overview. Int J Radiat Biol 60:401–408, 1991
10. Maione TE, Sharpe RJ: Development of angiogenesis inhibitors for clinical applications. Trends Pharmacol 11:457–461, 1990
11. Denekamp J, Hobson B: Endothelial-cell proliferation in experimental tumours. Br J Cancer 46:711–720, 1982
12. Crum R, Szabo S, Folkman J: A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230:1375–1378, 1985
13. Wellstein A, Zuomaier G, Califano J, et al: Xylanopolyhydrogensulfate inhibits fibroblast growth factor dependent growth of human tumor cells. Proc Am Assoc Cancer Res 30:2320, 1989
14. Wellstein A, Zugmaier G, Califano JA III, et al: Tumor growth dependent on Kaposi’s sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 83:716–720, 1991
15. Wellstein A, Lupu R, Zugmaier G, et al: Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1:63–71, 1990
16. Wellstein A, Fang WJ, Khatri A, et al: A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem 267:2582–2587, 1992
17. Higashiyama S, Lau K, Besner GE, et al: Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem 267:6205–6212, 1992
18. Lupu R, Colomer R, Zugmaier G, et al: Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and pl85erbB2. Science 249:1552–1555, 1990
19. Ennis BW, Valverius EM, Bates SE, et al: Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3:1830–1838, 1989
20. Bates SE, Davidson NE, Valverius EM, et al: Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: Its regulation by estrogen and its possible functional significance. Mol Endocrinol 2:543–555, 1988
21. Sporn MB, Roberts AB: Peptide growth factors are multifunctional. Nature 332:217–219, 1988
22. Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58:575–606, 1989
23. Halper J, Moses HL: Purification and characterization of a novel transforming growth factor. Cancer Res 47:4552–4559, 1987
24. Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature 313:745–747, 1985
25. Prestrelski SJ, Fox GM, Arakawa T: Binding of heparin to basic fibroblast growth factor induces a conformational change. Arch Biochem Biophys 293:314–319, 1992
26. Savona C, Chambaz EM, Feige JJ: Proteoheparan sulfates contribute to the binding of basic FGF to its high affinity receptors on bovine adrenocortical cells. Growth Factors 5:273–282, 1991
27. Sun XJ, Chang JY: The heparin and pentosan polysulfate binding sites of human antithrombin overlap but are not identical. Eur J Biochem 185:225–230, 1989
28. Ornitz DM, Yayon A, Flanagan JG, et al: Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol 12:240–247, 1992
29. Rapraeger AC, Krufka A, Olwin BB: Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252:1705–1708, 1991
30. Yayon A, Klagsbrun M, Esko JD, et al: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841–848, 1991
31. Ruoslahti E, Yamaguchi Y: Proteoglycans as modulators of growth factor activities. Cell 64:867–869, 1991
32. Newman ME: AIDS drug gets trial as cancer therapy. J Natl Cancer Inst 21:1671–1672, 1990
33. Parker BW, Swain SS, Stakeley K, et al: Detection of pentosanpolysulfate activity in patient serum using a bioassay. Proc Am Assoc Cancer Res 33:3112, 1992